France's Valneva 2025 revenue rises, reiterates FY revenue guidance

Valneva SE

18/03/2026 06:10

Overview

France vaccine maker's 2025 revenue rose slightly, driven by proprietary product sales

Net loss widened sharply due to absence of prior year one-off gain

Company reiterated 2026 revenue guidance and expects key clinical trial readouts

Outlook

Valneva expects 2026 total revenues between €155 mln and €170 mln

Company sees 2026 product sales between €145 mln and €160 mln

Valneva expects operating cash burn to decline further in 2026

Result Drivers

PROPRIETARY PRODUCT GROWTH - Higher sales of Japanese encephalitis and chikungunya vaccines supported revenue, offsetting lower third-party sales

MARGIN PRESSURE - Gross margins were affected by higher manufacturing costs, batch failures, and inventory write-offs

INCREASED R&D SPENDING - Higher research and development costs driven by Shigella vaccine program and chikungunya post-marketing obligations

Company press release: ID:nGNE8CwJsN

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-EUR 115.20 mln
FY Adjusted EBITDA
-EUR 59.40 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Valneva SE is €7.70, about 63% above its March 17 closing price of €4.72

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)